It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
Biointelect is a strategic planning and commercialisation firm for the biopharmaceutical and medical device sector including commercial, government and not-for-profit organisations.
Biointelect helps its clients develop and drive strategy, identify and evaluate new business opportunities and engage the right partners. The strategy consulting involves therapeutic development from start up through to post launch, with an Australian and a Global perspective.
Biointelect’s mission is to bring science to market.
Biocelect works with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market.
In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand.
Biocelect’s mission is to build pathways to patients.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Lasers in dental treatment without needles and drills
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
-
Taiwanese health and research delegation visit Paratus clinical trial site in Canberra
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
-
CASE STUDY: Creating awareness, workforce education & dissemination strategy in national screening
At the recent Screening Conference 2025 in Sydney, hosted by Public Health Association, Dr Rachael Dodd, Senior Research Fellow at The Daffodil Centre, spoke about the information and educational resources created to increase awareness in the healthcare workforce and community on the upcoming Australia’s National Lung Cancer Screening Program commencing in July 2025.
